Krka d. d (KRK) - Total Liabilities
Based on the latest financial reports, Krka d. d (KRK) has total liabilities worth zł662.58 Million PLN (≈ $182.35 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Krka d. d generate cash to assess how effectively this company generates cash.
Krka d. d - Total Liabilities Trend (2010–2024)
This chart illustrates how Krka d. d's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Krka d. d to evaluate the company's liquid asset resilience ratio.
Krka d. d Competitors by Total Liabilities
The table below lists competitors of Krka d. d ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sartorius Aktiengesellschaft
XETRA:SRT3
|
Germany | €5.80 Billion |
|
BrightSpring Health Services, Inc. Common Stock
NASDAQ:BTSG
|
USA | $4.53 Billion |
|
Campbell’s Co
NYSE:CPB
|
USA | $10.99 Billion |
|
Zhejiang Jingsheng Mech Electric
SHE:300316
|
China | CN¥9.51 Billion |
|
Oracle Financial Services Software Limited
NSE:OFSS
|
India | Rs19.38 Billion |
|
Baiyin Nonferrous Group Co Ltd
SHG:601212
|
China | CN¥35.05 Billion |
|
Zions Bancorporation
NASDAQ:ZION
|
USA | $81.67 Billion |
Liability Composition Analysis (2010–2024)
This chart breaks down Krka d. d's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Krka d. d worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.91 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Krka d. d's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Krka d. d (2010–2024)
The table below shows the annual total liabilities of Krka d. d from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | zł611.24 Million ≈ $168.22 Million |
+4.93% |
| 2023-12-31 | zł582.52 Million ≈ $160.32 Million |
+6.11% |
| 2022-12-31 | zł548.99 Million ≈ $151.09 Million |
-11.25% |
| 2021-12-31 | zł618.60 Million ≈ $170.25 Million |
+27.88% |
| 2020-12-31 | zł483.73 Million ≈ $133.13 Million |
-6.45% |
| 2019-12-31 | zł517.10 Million ≈ $142.31 Million |
+16.26% |
| 2018-12-31 | zł444.80 Million ≈ $122.42 Million |
+3.10% |
| 2017-12-31 | zł431.43 Million ≈ $118.74 Million |
-7.63% |
| 2016-12-31 | zł467.07 Million ≈ $128.55 Million |
+15.84% |
| 2015-12-31 | zł403.22 Million ≈ $110.97 Million |
-9.15% |
| 2014-12-31 | zł443.85 Million ≈ $122.15 Million |
+3.88% |
| 2013-12-31 | zł427.27 Million ≈ $117.59 Million |
+10.63% |
| 2012-12-31 | zł386.23 Million ≈ $106.30 Million |
-2.04% |
| 2011-12-31 | zł394.27 Million ≈ $108.51 Million |
-9.34% |
| 2010-12-31 | zł434.88 Million ≈ $119.68 Million |
-- |
About Krka d. d
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company's prescription pharmaceuticals include medicines for the treatment of cardiovascular, gastrointestinal tract and metabolis… Read more